An enolase inhibitor for the targeted treatment of ENO1-deleted cancers

Affiliations

• 1 Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• 2 Institute of Stroke and Cerebrovascular Disease, University of Texas Health Science Center at Houston, Houston, TX, USA.
• 3 Institutional Analytics & Informatics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• 4 Cardtronics, Inc, Houston, TX, USA.
• 5 Core for Biomolecular Structure and Function, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• 6 Institute for Applied Cancer Sciences, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• 7 Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• 8 Pharmaceutical Science Facility, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• 9 Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
• 10 Director of Drug Discovery and Development, Advanced Organic Synthesis LLC, Houston, Texas, USA.
• 11 Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• 12 Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• 13 Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA. aettius@aol.com.